The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

Author: BlauwG J, BollenE L, BuckleyB M, CobbeS M, FordI, GawA, HylandM, JukemaJ W, LagaayA M, MacfarlaneP W, MeindersA E, MurphyM B, PackardC J, PerryI J, ShepherdJ, StottD J, SweeneyB J, TwomeyC, WestendorpR G

Paper Details 
Original Abstract of the Article :
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, double-blind, placebo-controlled trial designed to test the hypothesis that treatment with pravastatin will diminish risk of subsequent major vascular events in a cohort of men and women (70 to 82 years old) with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/s0002-9149(99)00533-0

データ提供:米国国立医学図書館(NLM)

Preventing the Sands of Time: Pravastatin and the Elderly at Risk

As we age, our bodies become more susceptible to heart disease and other vascular problems. Imagine aging as a journey across a vast desert, where the sands of time can erode our health. This study investigates the potential benefits of pravastatin, a cholesterol-lowering medication, in reducing the risk of major vascular events in elderly individuals. The researchers conducted a large randomized, double-blind, placebo-controlled trial involving 5,804 participants aged 70 to 82 years with preexisting vascular disease or a high risk of developing it. The study aims to determine if pravastatin can help prevent cardiovascular events and improve overall health in this vulnerable population.

Protecting the Elderly from Vascular Threats

This study highlights the importance of managing cardiovascular risk in the elderly population. The researchers hope to demonstrate the potential of pravastatin in reducing the risk of heart disease and stroke, contributing to better health outcomes for this vulnerable group.

A Proactive Approach to Cardiovascular Health

The study emphasizes the importance of preventive measures for cardiovascular health, particularly in the elderly. Maintaining a healthy lifestyle, including regular exercise, a balanced diet, and regular medical checkups, is essential for reducing cardiovascular risks.

Dr.Camel's Conclusion

This study is like a seasoned caravan leader, guiding us through the challenges of aging. The research is exploring the potential of pravastatin to protect the elderly from the threats of vascular disease, ensuring a smoother and healthier journey through the sands of time.

Date :
  1. Date Completed 1999-12-02
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

10569329

DOI: Digital Object Identifier

10.1016/s0002-9149(99)00533-0

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.